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 OPEN ACCESS 
Tuberculosis in the history of infectious 
diseases
History of Medicine is not a discipline destined to culturally 
enrich only those who work in the health sector. All historians 
know very well how some medical events have influenced 
the course of history. In particular, infectious diseases, being 
interconnected with geo-political, social, economic and war-
related issues, have an important historical significance [1]. 
Some of the classic examples are the plague epidemics 
that occurred in the 6th, 14th and 17th centuries [2], syphilis 
considered as the disease imported from the new world [3], 
the pandemic Spanish influence of 1918 [4] and now the 
pandemic SARS-CoV-2 (COVID-19). 
The diseases listed above have dramatically marked the history 
of humanity, with events that can be clearly defined with a 
start date and an end date, except for the COVID-19 which 
is still ongoing now. Other pathologies, such as malaria [5, 6] 
and schistosomiasis [7], have taken root as endemic diseases 
and they have been timeless enemies for some peoples.
Tuberculosis (TB) is an ancient scourge. It has plagued 
humankind throughout known history and human 
prehistory. It has surged in great epidemics and then 
regressed, thus acting like other infectious diseases, but 
with a time scale that challenges accepted explanations for 
epidemic cycles. Mycobacterium tuberculosis may have 
killed more persons than any other microbial pathogen [8].
The coexistence of man and tuberculosis: 
historical and social aspects
Modern strains of Mycobacterium tuberculosis appear to 
have originated from a common ancestor about 15,000-
20,000 years ago [9, 10].
The first tuberculosis infections are demonstrated in the 
most ancient civilizations. Tuberculosis in Egypt has been 
documented more than 5,000 years ago.
Skeletal abnormalities associated with tuberculosis, 
including characteristic Pott’s deformities, have been 
found in Egyptian mummies (confirmed by DNA analysis 
in mummified tissues) and are clearly depicted in early 
Egyptian art.
Tuberculosis is clearly noted in the Biblical books of 
Deuteronomy and Leviticus, however, using the ancient 
Hebrew word “schachepheth” [8].
In the collective imagination, people living in a condition 
of socio-economic decay become ill with tuberculosis; 
this association could have been decisive to create the 
“Pulcinella” character, a stereotype of the poor peasant.
“Pulcinella”, mainly known in the English-speaking world 
as “Mr Punch”, is a character from the Italian Commedia 
dell’Arte, whose origins can be traced back to protagonists 
of Roman Atellan comedy (e.g. Maccus or Bucco), whose 
grotesque appearances closely resemble the 16th century 
Neapolitan mask.
This character, as we know him today, originated in Naples 
(city sadly known for tuberculosis epidemics), most likely 
representing a poor and hungry, ready to steal food even at 
the cost of cheating and lying [11, 12].
This character may well be analyzed in an ethnological 
and anthropological fashion, with his distinctive physical 
appearance being exaggeratedly hook-nosed, back-
humped, and with a paunch/ lumbar lordosis. A similar 
spinal deformation may be caused by tuberculosis in 
its form known as Pott’s disease, the most widespread 
tubercular osteo-articular presentation, capable of affecting 
every segment of the rachis, albeit more commonly the 
lowermost section of the thoracic column and the lumbar 
tract [12].
This overview shows how tuberculosis has represented and still rep-
resents a continuous challenge for Medicine. Starting from the dawn 
of medicine, when tuberculosis was called “phthisis” by Hippocrates, 
passing through the discovery of the tubercles and the creation of the 
word “tuberculosis”, following the application of the anatomo-clini-
cal method, until the discovery of a microscopic enemy: Mycobacte-
rium tuberculosis. The progressive discovery of the pathological basis 
of tuberculosis has allowed to devise important therapeutic strategies 
in Pre-Antibiotic and Post-Antibiotic Era. In particular, “antibiotic 
therapy” had to be the end of the challenge between man and tuber-
culosis. However it was only an illusion. Despite progress in care and 
prevention, tuberculosis remains one of the world’s leading causes of 
ill-health and the first cause of death from infectious disease. Nowa-
days, the drug resistance, individuals with immune deficiencies, the 
ageing and globalization are just some of the causes responsible for 
the increasing of the challenge between man and tuberculosis.
REVIEW
Tuberculosis: a timeless challenge for medicine
E. ARMOCIDA1, M. MARTINI2,3
1 Department of Medicine and Surgery, University of Parma, Italy; 2 Department of Health Sciences, University of Genoa, Italy; 
3 Unesco Chair “Anthropology of Health - Biosphere and Healing System” University of Genoa, Italy
Keywords
Tuberculosis • History • Infectious disease • Mycobacterium tuberculosis • Antibiotic Era
Summary
E. ARMOCIDA, M. MARTINI
E144
Traditional puppets with social and somatic characteristics 
similar to those of “Pulcinella”, a poor peasant with a hump, 
are present in the folklore of different European states.
Ancient Medicine: when tuberculosis 
was called phthisis
In the history of medicine, tuberculosis is well suited to 
study the epistemological path of medical thought, from its 
origins to the present day.
Tuberculosis was well known by Hippocrates, who is 
universally recognized as the father of medicine. He clearly 
recognized tuberculosis, where it was called phthisis, and 
understood its clinical presentation. “Phthisis makes its 
attacks chiefly between the age of eighteen and thirty-
five,” he wrote in his aphorisms, clearly recognizing the 
predilection of young adults for active tuberculosis [13].
“Consumption was the most considerable of the diseases 
which then prevailed, and the only one which proved fatal to 
many persons,” he wrote in Book I, Of the Epidemics [14].
Another Greek physician who has a pivotal role in the 
history of medicine is Clarissimus Galen. He became 
physician to Roman Emperor Marcus Aurelius in 174. He 
wrote of tuberculosis and recommended fresh air, milk, and 
sea voyages for its treatment, but the disease does not have 
prominence in his medical texts [8].
The anatomical revolution in the history 
of tuberculosis
With the beginning of the Middle Ages, scientific progress 
stopped, even in the medical field. Hippocratic and Galenic 
knowledge was studied and applied to clinic in a dogmatic 
manner, being considered absolute truths.
Although starting from the 14th century, Mondino de 
Liuzzi (1275-1326) began to verify on cadavers the notions 
handed down by the fathers of medicine, thus starting the 
experimental sciences.
It has been necessary to wait centuries before the scientific 
approach had a confirmation in clinical practice and thus 
physicians abandoned humoral theories. In the study 
of tuberculosis the transition from the dogmatic to the 
experimental approach has been particularly slow.
In the 17th century Marcello Malpighi (1628-1694) 
introduced the use of the microscope in anatomy.
Thanks to this instrument he was able to describe the 
anatomical structure of the lung [15]. 
In 1689 the English physician Richard Morton (1637-
1698), contemporary of Malpighi, was the first to state that 
tubercles were always present in the lungs suffering from 
phthisis [16]. 
As the result of 900 post-mortem investigations, in 1810 
Gaspar Laurent Bayle (1774-1816) described that tubercles 
could also be detected in organs other than the lung [17, 18].
Thanks to the incessant study of corpse René Théophile 
Hyacinthe Laennec (1781-1826), who was a colleague to 
Bayle, laid the foundation for a modern clinic understanding 
of tuberculosis [8, 19].
In 1819 he published a treatise that not only clearly 
expounded the pathology of tuberculosis unifiying 
the concept of the disease, whether pulmonary or 
extrapulmonary, but also described most of the physical 
signs of pulmonary disease, introducing terms to describe 
those findings that are still in use today [20].
In 1839 Johann Lukas Schönlein (1793-1864) coined the 
term “tuberculosis” replacing the terms consumption and 
phthisis that were used in the 17th and 18th centuries [21].
The discovery of a microscopic enemy: 
Mycobacterium tuberculosis
Although many important anatomopathological and 
clinical aspects of the tuberculosis were clarified, its 
etiopathogenesis remained unknown.
In Northern Europe tuberculosis was generally considered 
a heritable disease; in Southern Europe it was felt to be 
infectious in nature. 
That tuberculosis was, indeed, infectious in nature was 
probably first suggested in 1720 by Benjamin Marten 
(c.  1690-1752), who attributed the disease to “some 
certain species of animalcula” [22]. The infectious nature 
of phthisis was demonstrated in 1865 by Jean-Antoine 
Villemin (1827-1892), a French military surgeon at the 
Army Medical School.
He formulated his hypothesis observing that tuberculosis 
was more frequent among soldiers who stationed for long 
times in barracks than among those in the field. He also 
highlighted how healthy army recruits coming from the 
countryside often became consumptive some months after 
the beginning of their service. He infected a rabbit with “a 
small amount of purulent liquid from a tuberculous cavity” 
removed at autopsy from an individual who had died of 
tuberculosis [21].
On the evening of March 24, 1882, Robert Koch (1843-
1910) presented the discovery of the infectious cause of 
tuberculosis at the Berlin Physiological Society.
Koch summarized the importance of his findings, for 
which he received the 1905 Nobel Prize, in a manuscript 
published in the Berliner Klinische Wochenschrift shortly 
after his announcement: “In the future the fight against 
this terrible plague of mankind will deal no longer with 
an undetermined something, but with a tangible parasite, 
whose living conditions are for the most part known and 
can be investigated further” [23, 24].
Koch’s studies on tuberculosis are a milestone in the history 
of medicine: they inaugurated the beginning of the reign of 
bacteriology in hygiene. 
The social history of medicine has placed Koch’s early 
work on tuberculosis at the outset of the bacteriological era 
in hygiene and public health that led to the “medicalization” 
of entire societies in the late 19th century. 
The new bacteriologists’ conception of the pathogens 
stripped epidemics of any political meaning, turned them 
into exclusive objects of scientific investigation, lending 
legitimacy to extended positivism based on medical 
expertise [25].
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Tuberculosis therapy in the Pre-Antibiotic Era
Despite the fundamental diagnostic advances that occurred 
in the nineteenth century, therapeutic solutions for 
tuberculosis were still immature.
In the second half of the 19th century, it was a common 
conviction that specific climatic environments could 
contribute to cure tuberculosis. Subsequently, the most 
frequently prescribed remedy for pulmonary forms was a 
stay in a temperate climate.
In Europe, the first sanatorium was founded in 1854 by 
Hermann Brehmer in Germany, in Goebersdorf in Slesia, 
a village on the border between Poland and the Czech 
Republic. Brehmer stressed the therapeutic effect of the 
climate in the treatment of phthisis.
The sanatorium regimen planned to cure tuberculosis with 
Galenic principles of hygiene: isolation, fresh air, exercise 
and good nutrition.
Eminent physicians supported these remedy for the 
treatment of the most serious forms of the disease for a few 
decades [26].
People suffering from tuberculosis became often ill also 
because of their socio-economic conditions. The correct 
lifestyle offered in sanatoriums could help patients to 
rehabilitate themselves and find the strength necessary to 
defeat the disease. Furthermore, the isolation of tuberculosis 
carriers protected the population from infection.
These two functions were the only medical goals that could 
be hoped for from a sanatorium. The seriously ill were 
unlikely to benefit from staying in the sanatorium [8, 27].
For this reason, in the first half of the 20th century, numerous 
preventoria were opened.
They had a preventive function: they housed healthy 
children potentially at risk of infection. In these facilities 
the guests had the opportunity to respect the main hygienic 
rules and to feed themselves correctly, as in the sanatorium, 
keeping themselves healthy [28, 29].
The second therapeutic strategy for the treatment of 
tuberculosis was the therapeutic pneumothorax. The first 
successful therapeutic pneumothorax was induced by F.H. 
Ramadge in London in 1834; he reported complete healing 
of his patient. Carlo Forlanini (1847-1918) is remembered 
as the inventor of artificial pneumothorax for treatment 
of pulmonary tuberculosis. He carefully documented his 
results with artificial pneumothorax in 1894, and thereafter 
the procedure became widely used [30]. It is probable that 
pneumothorax was a useful therapy, primarily because it 
often resulted in cavity closure and sputum conversion 
to negative. In 1913 and 1914, Forlanini, thanks to his 
discovery, was on the shortlist of the Nobel Committee 
and thus one of the prime candidates for the prestigious 
prize [31].
However, there are no controlled studies of its efficacy – it 
is difficult to know how one could design such trials – and 
one must rely on reviews of series of treated patients [8].
In 1890 Robert Koch developed tuberculin, a glycerine 
extract of the tubercle bacilli, as a remedy for tuberculosis, 
but reductions in deaths did not meet those expected of the 
treatment [25]. However, thanks to the studies of Koch, the 
tuberculin skin test has been developed and are still used in 
the diagnosis of tuberculosis.
In 1900 Albert Calmette and Camille Guérin began their 
research for an antituberculosis vaccine at the Pasteur 
Institute in Lille and, in 1921, the time was ripe for a trial 
of the vaccine, called Bacille Calmette-Guérin (BCG), in 
man.
Vaccines have changed the history of many infectious 
diseases, the most illuminating example is the eradication 
of smallpox. BCG has not had the same luck.
Although the efficacy of the BCG vaccine continues to be 
controversial, live attenuated BCG is still the only vaccine 
in use for the prevention of tuberculosis in humans [32].
Antibiotics: turning point in the fight 
against tuberculosis
The optimism brought by Koch’s discovery had no 
significant consequences in medical practice for over 
60 years. 
The first truly effective anti-tuberculosis drug arrived in 
1943: streptomycin, isolated in the laboratory of Selman 
Waksman at Rutgers University. In November 1944, a 
patient with tuberculosis received streptomycin and was 
declared healed from the disease.
Other cases of successful treatment soon followed [33, 34]. 
Streptomycin was among the first antibiotic molecules 
on the market. Again, we find that tuberculosis has been 
involved in an epochal shift in the history of medicine: the 
advent of the antibiotic era.
The British Medical Research Council conducted the first 
large-scale clinical trial of streptomycin in 1948 [35].
This study, said to be the world’s first published drug trial 
that involved the randomization of participants, set the 
methodologic standard for modern randomized controlled 
trials. In 1951, isonicotinic acid hydrazide (isoniazid) was 
tested, followed by the development of pyrazinamide 
(1952), cycloserine (1952), ethionamide (1956), rifampin 
(1957), and ethambutol (1962) [34].
The introduction of antibiotics in a short time has radically 
changed medical practice.
This change can be documented in the medical literature 
intended for the general practitioner. For example, in Italy 
the Anton Spartaco Roversi’s Manual of Medicine was a 
consultation pocket book that tried to give an comprehensive 
overview about medical practice in order to provide a useful 
bed-side tool for generations of Italian physicians.
In its first editions (1940 and 1944) tuberculosis was 
finely explained in a systematic manner in every possible 
manifestation within the chapters divided by organ “With 
the arrival of effective antibiotic therapies, in the subsequent 
editions of the book (1954 and 1967) there has been a 
drastic drop in the number of pages devoted to tuberculosis 
and its manifestations, indicating a decreased finding of 
extrapulmonary complications of the disease, and therefore 
a decreased interest for the general practitioner” [36].
Optimism that tuberculosis would soon be eliminated was 
not restricted to wealthy countries. At the 1978 International 
Conference on Primary Health Care in Alma-Ata (now 
E. ARMOCIDA, M. MARTINI
E146
called Almaty), Kazakhstan, delegates from around the 
world endorsed the goal of “health for all by the year 2000.” 
The eradication of smallpox had been announced the 
previous year, and the future of international public health 
looked promising to many who were gathered there. But it 
was not to be.
Tuberculosis therapy in the Post-Antibiotic Era
The enthusiasm for the success of anti-tuberculosis 
drug therapy stifled the alarm bells that did start to ring 
around the limits of antibiotic therapy.
Studies on tuberculosis in the 1950s anticipated a 
problem of great relevance today, anti-antibiotic 
resistance. Once again, tuberculosis is the protagonist in 
an epochal change in medicine: the post-antibiotic era.
The first national drug-resistance survey in the world, 
which involved 974 clinical isolates cultured from newly 
diagnosed cases of tuberculosis in Britain (1955-1956), 
showed strains that were resistant to streptomycin (2.5%), 
para-aminosalicylic acid (2.6%), and isoniazid (1.3%) [34].
Tuberculosis, whether caused by drug-susceptible 
or drug-resistant strains, rarely made even medical 
headlines, in part because its importance as a cause of 
death continued to decline in areas in which headlines 
are written. In such settings, where many of the social 
determinants of tuberculosis - extreme poverty, severe 
malnutrition, and overcrowded living conditions - 
became the exception rather than the norm, some public 
health experts declared that “virtual elimination of the 
disease as a public health problem” was in sight [37].
Currently, what are the challenges  
that tuberculosis offers to us?
Despite progress in care and prevention, tuberculosis 
remains one of the world’s leading causes of ill-health and 
death and the top cause of death from an infectious disease 
globally [38]. The fight against drug resistance is only a tile 
of an always changing mosaic that needs constant attention 
and innovation in therapeutic strategies [39, 40].
Globalization is improving circulation of people, goods, 
but also of microbial agents which may find favorable 
habitats. Individuals with immune deficiencies represent 
an ever-increasing population at higher risk of contracting 
tuberculosis. Co-infection with HIV is also a new scenario 
where doctors have to fight tuberculosis [41].
At last, we must remember that ageing makes people 
particularly fragile versus tuberculosis, since it decreases the 
efficiency of the immune system and increases difficulty in 
tolerating side effects of anti-tuberculosis drugs, sometimes 
lethal [42, 43].
As often happens in the management of infectious diseases, 
only comprehensive approaches that aim to tackle down 
social determinants of tuberculosis, coupled with scientific 
progress in diagnostic and therapeutic management of 
patients with tuberculosis, may allow to eradicate this 
disease in heavily affected countries [44].
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